» Articles » PMID: 35453408

Mitochondrial-Targeted Therapies Require Mitophagy to Prevent Oxidative Stress Induced by SOD2 Inactivation in Hypertrophied Cardiomyocytes

Abstract

Heart failure, mostly associated with cardiac hypertrophy, is a major cause of illness and death. Oxidative stress causes accumulation of reactive oxygen species (ROS), leading to mitochondrial dysfunction, suggesting that mitochondria-targeted therapies could be effective in this context. The purpose of this work was to determine whether mitochondria-targeted therapies could improve cardiac hypertrophy induced by mitochondrial ROS. We used neonatal (NCMs) and adult (ACMs) rat cardiomyocytes hypertrophied by isoproterenol (Iso) to induce mitochondrial ROS. A decreased interaction between sirtuin 3 and superoxide dismutase 2 (SOD2) induced SOD2 acetylation on lysine 68 and inactivation, leading to mitochondrial oxidative stress and dysfunction and hypertrophy after 24 h of Iso treatment. To counteract these mechanisms, we evaluated the impact of the mitochondria-targeted antioxidant mitoquinone (MitoQ). MitoQ decreased mitochondrial ROS and hypertrophy in Iso-treated NCMs and ACMs but altered mitochondrial structure and function by decreasing mitochondrial respiration and mitophagy. The same decrease in mitophagy was found in human cardiomyocytes but not in fibroblasts, suggesting a cardiomyocyte-specific deleterious effect of MitoQ. Our data showed the importance of mitochondrial oxidative stress in the development of cardiomyocyte hypertrophy. We observed that targeting mitochondria by MitoQ in cardiomyocytes impaired the metabolism through defective mitophagy, leading to accumulation of deficient mitochondria.

Citing Articles

Mitophagy is required to protect against excessive skeletal muscle atrophy following hindlimb immobilization.

Rahman F, Graham M, Adam A, Juracic E, Tupling A, Quadrilatero J J Biomed Sci. 2025; 32(1):29.

PMID: 39979946 PMC: 11844018. DOI: 10.1186/s12929-025-01118-w.


HSP90 Enhances Mitophagy to Improve the Resistance of Car-Diomyocytes to Heat Stress in Wenchang Chickens.

Shi J, Ji Z, Yao X, Yao Y, Li C, Liang Q Int J Mol Sci. 2024; 25(21).

PMID: 39519247 PMC: 11546521. DOI: 10.3390/ijms252111695.


Proteome-wide Characterization and Pathophysiology Correlation in Non-ischemic Cardiomyopathies.

Lee S, Jang D, Kyoung Y, Kim J, Kim E, Hwang I Korean Circ J. 2024; 54(8):468-481.

PMID: 38956938 PMC: 11306425. DOI: 10.4070/kcj.2024.0033.


SIRT3 Is a Critical Regulator of Mitochondrial Function of Fibroblasts in Pulmonary Hypertension.

Li M, Plecita-Hlavata L, Dobrinskikh E, McKeon B, Gandjeva A, Riddle S Am J Respir Cell Mol Biol. 2023; 69(5):570-583.

PMID: 37343939 PMC: 10633840. DOI: 10.1165/rcmb.2022-0360OC.


Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets.

Correale M, Tricarico L, Croella F, Alfieri S, Fioretti F, Brunetti N Front Cardiovasc Med. 2023; 10:1157472.

PMID: 37332581 PMC: 10272855. DOI: 10.3389/fcvm.2023.1157472.


References
1.
Lu J, Cheng K, Zhang B, Xu H, Cao Y, Guo F . Novel mechanisms for superoxide-scavenging activity of human manganese superoxide dismutase determined by the K68 key acetylation site. Free Radic Biol Med. 2015; 85:114-26. DOI: 10.1016/j.freeradbiomed.2015.04.011. View

2.
Dubois E, Richard V, Mulder P, Lamblin N, Drobecq H, Henry J . Decreased serine207 phosphorylation of troponin T as a biomarker for left ventricular remodelling after myocardial infarction. Eur Heart J. 2010; 32(1):115-23. DOI: 10.1093/eurheartj/ehq108. View

3.
Morales P, Arias-Duran C, Avalos-Guajardo Y, Aedo G, Verdejo H, Parra V . Emerging role of mitophagy in cardiovascular physiology and pathology. Mol Aspects Med. 2019; 71:100822. DOI: 10.1016/j.mam.2019.09.006. View

4.
Sabbah H . Targeting mitochondrial dysfunction in the treatment of heart failure. Expert Rev Cardiovasc Ther. 2016; 14(12):1305-1313. DOI: 10.1080/14779072.2016.1249466. View

5.
Turkieh A, Fertin M, Bouvet M, Mulder P, Drobecq H, Lemesle G . Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction. Circ Heart Fail. 2018; 11(6):e004838. DOI: 10.1161/CIRCHEARTFAILURE.117.004838. View